GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Total Stockholders Equity

VolitionRX (VolitionRX) Total Stockholders Equity : $-7.80 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is VolitionRX Total Stockholders Equity?

VolitionRX's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.80 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. VolitionRX's Book Value per Share for the quarter that ended in Dec. 2023 was $-0.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. VolitionRX's Debt-to-Equity for the quarter that ended in Dec. 2023 was -0.75.

VolitionRX Total Stockholders Equity Historical Data

The historical data trend for VolitionRX's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX Total Stockholders Equity Chart

VolitionRX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.20 16.34 17.94 -2.58 -7.80

VolitionRX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 -2.34 5.84 -2.04 -7.80

VolitionRX  (AMEX:VNRX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

VolitionRX's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-7.802-0)/81.8983
=-0.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

VolitionRX's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.455 + 4.403) / -7.802
=-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VolitionRX Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of VolitionRX's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

VolitionRX (VolitionRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Total Stockholders Equity
Comparable Companies
BIOQ DMTK DRIO ENZ PRE AWH ACRS XGN CNTG PRPH TMO DHR IDXX IQV A XSWX:LONN SHSE:603259 MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Website
https://www.volition.com
VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Executives
Eight Corp Ltd 10 percent owner C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert director, officer: SECRETARY 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds director, officer: PRESIDENT AND CEO 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall director 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef officer: Chief Scientific Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan other: Manager Belgian Volition SPRL 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway other: CEO-Singapore Volition 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer officer: GC - Volition Diagnostics 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor officer: Group Chief Marketing Officer 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md officer: Chief Medical Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014